{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:09:12Z","timestamp":1792440552353,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,11,29]],"date-time":"2007-11-29T00:00:00Z","timestamp":1196294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1007\/s00228-007-0404-3","type":"journal-article","created":{"date-parts":[[2007,11,27]],"date-time":"2007-11-27T18:20:41Z","timestamp":1196187641000},"page":"275-282","source":"Crossref","is-referenced-by-count":39,"title":["Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI)"],"prefix":"10.1007","volume":"64","author":[{"given":"Ksenia","family":"Goryachkina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Burbello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Boldueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Babak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Bertilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,11,29]]},"reference":[{"issue":"2","key":"404_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000083165","volume":"74","author":"C Sorensen","year":"2005","unstructured":"Sorensen C, Friis-Hasche E, Haghfelt T, Bech P (2005) Postmyocardial infarction mortality in relation to depression: a systematic critical review. Psychother Psychosom 74(2):69\u201380","journal-title":"Psychother Psychosom"},{"issue":"1","key":"404_CR2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1525-1497.2005.00269.x","volume":"21","author":"BD Thombs","year":"2006","unstructured":"Thombs BD, Bass EB, Ford DE et al (2006) Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med 21(1):30\u201338","journal-title":"J Gen Intern Med"},{"issue":"3","key":"404_CR3","first-page":"29","volume":"47","author":"EI Chazov","year":"2007","unstructured":"Chazov EI, Oganov RG, Pogosova GV et al (2007) Clinico-epidemiological program of the study of depression in cardiological practice in patients with arterial hypertension and ischemic heart disease (COORDINATA). Kardiologiia 47(3):29\u201337","journal-title":"Kardiologiia"},{"issue":"5","key":"404_CR4","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.ahj.2005.01.041","volume":"150","author":"W Jiang","year":"2005","unstructured":"Jiang W, Davidson JR (2005) Antidepressant therapy in patients with ischemic heart disease. Am Heart J 150(5):871\u2013881","journal-title":"Am Heart J"},{"issue":"2\u20133","key":"404_CR5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(97)01393-9","volume":"340","author":"M Tatsumi","year":"1997","unstructured":"Tatsumi M, Groshan K, Blakely RD, Richelson E (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340(2\u20133):249\u2013258","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"404_CR6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000079172.43229.CD","volume":"108","author":"WH Sauer","year":"2003","unstructured":"Sauer WH, Berlin JA, Kimmel SE (2003) Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 108(1):32\u201336","journal-title":"Circulation"},{"issue":"4","key":"404_CR7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jama.279.4.287","volume":"279","author":"SP Roose","year":"1998","unstructured":"Roose SP, Laghrissi-Thode F, Kennedy JS et al (1998) Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 279(4):287\u2013291","journal-title":"Jama"},{"issue":"2","key":"404_CR8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00004714-200004000-00004","volume":"20","author":"BG Pollock","year":"2000","unstructured":"Pollock BG, Laghrissi-Thode F, Wagner WR (2000) Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 20(2):137\u2013140","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"404_CR9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0006-3223(02)01394-X","volume":"52","author":"VK Yeragani","year":"2002","unstructured":"Yeragani VK, Pohl R, Balon R, Ramesh C, Glitz D et al (2002) Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biol Psychiatry 52(5):418\u2013429","journal-title":"Biol Psychiatry"},{"issue":"6","key":"404_CR10","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jama.288.6.701","volume":"288","author":"AH Glassman","year":"2002","unstructured":"Glassman AH, O\u2019Connor CM, Califf RM et al (2002) Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288(6):701\u2013709","journal-title":"Jama"},{"issue":"2","key":"404_CR11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00228-004-0877-2","volume":"61","author":"E Molden","year":"2005","unstructured":"Molden E, Garcia BH, Braathen P, Eggen AE (2005) Co-prescription of cytochrome P450 2D6\/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies. Eur J Clin Pharmacol 61(2):119\u2013125","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"404_CR12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1389200023338017","volume":"3","author":"A Hemeryck","year":"2002","unstructured":"Hemeryck A, Belpaire FM (2002) Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 3(1):13\u201337","journal-title":"Curr Drug Metab"},{"issue":"6 Pt 2","key":"404_CR13","first-page":"I26","volume":"67","author":"A Hjalmarson","year":"1983","unstructured":"Hjalmarson A, Herlitz J, Holmborg S et al (1983) The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation 67(6 Pt 2):I26\u2013I32","journal-title":"Circulation"},{"issue":"9497","key":"404_CR14","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(05)67661-1","volume":"366","author":"ZM Chen","year":"2005","unstructured":"Chen ZM, Pan HC, Chen YP et al (2005) Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366(9497):1622\u20131632","journal-title":"Lancet"},{"issue":"7200","key":"404_CR15","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","volume":"318","author":"N Freemantle","year":"1999","unstructured":"Freemantle N, Cleland J, Young P et al (1999) Beta blockade after myocardial infarction: systematic review and meta regression analysis. Br Med J 318(7200):1730\u20131737","journal-title":"Br Med J"},{"issue":"6","key":"404_CR16","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0735-1097(85)80360-0","volume":"5","author":"G Olsson","year":"1985","unstructured":"Olsson G, Rehnqvist N, Sjo\u2019gren A, Erhardt L, Lundman T (1985) Long-term treatment with metoprolol after myocardial infarction: effect on 3\u00a0year mortality and morbidity. J Am Coll Cardiol 5(6):1428\u20131437","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"404_CR17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s002280050332","volume":"53","author":"B Everts","year":"1997","unstructured":"Everts B, Karlson B, Abdon N-J, Herlitz J, Hedner T et al (1997) Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. Eur J Clin Pharmacol 53(1):23\u201331","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"404_CR18","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2125.1985.tb05112.x","volume":"20","author":"JC McGourty","year":"1985","unstructured":"McGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF et al (1985) Metoprolol metabolism and debrisoquine oxidation polymorphism-population and family studies. Br J Clin Pharmacol 20(6):555\u2013566","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"404_CR19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","volume":"5","author":"M Ingelman-Sundberg","year":"2005","unstructured":"Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5(1):6\u201313","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"404_CR20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00228-003-0606-2","volume":"59","author":"EA Gaikovitch","year":"2003","unstructured":"Gaikovitch EA, Cascorbi I, Mrozikiewicz PM et al (2003) Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 59(4):303\u2013312","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"404_CR21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00008571-200208000-00007","volume":"12","author":"T Rau","year":"2002","unstructured":"Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J et al (2002) Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 12(6):465\u2013472","journal-title":"Pharmacogenetics"},{"issue":"2","key":"404_CR22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1023\/A:1021188315536","volume":"134","author":"GV Ramenskaya","year":"2002","unstructured":"Ramenskaya GV et al (2002) Pheno- and genotyping the prescription of drugs metabolized by CYP2D6. Bull Exp Biol Med 134(2):159\u2013160","journal-title":"Bull Exp Biol Med"},{"issue":"4","key":"404_CR23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1067\/mcp.2002.127111","volume":"72","author":"H Wuttke","year":"2002","unstructured":"Wuttke H, Rau T, Heide R, Bergmann K, B\u00f6hm M et al (2002) Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 72(4):429\u2013437","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"404_CR24","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.clpt.2005.07.004","volume":"78","author":"R Fux","year":"2005","unstructured":"Fux R, Morike K, Prohmer AM et al (2005) Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 78(4):378\u2013387","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"404_CR25","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.clpt.2004.08.020","volume":"76","author":"I Zineh","year":"2004","unstructured":"Zineh I, Beitelshees AL, Gaedigk A, Walker JR et al (2004) Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 76(6):536\u2013544","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"404_CR26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1067\/mcp.2000.104788","volume":"67","author":"A Hemeryck","year":"2000","unstructured":"Hemeryck A, Lefebvre RA, De Vriendt C, Belpaire FM (2000) Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 67(3):283\u2013291","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"404_CR27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF00562615","volume":"17","author":"MJ Kendall","year":"1980","unstructured":"Kendall MJ, John VA, Quarterman CR, Welling PG (1980) A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol. Eur J Clin Pharmacol 17(2):87\u201392","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"404_CR28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361\u2013370","journal-title":"Acta Psychiatr Scand"},{"key":"404_CR29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56\u201362","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5\u20136","key":"404_CR30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1050-3862(98)00019-9","volume":"14","author":"KJ Livak","year":"1999","unstructured":"Livak KJ (1999) Allelic discrimination using fluorogenic probes and the 5\u2032 nuclease assay. Genet Anal 14(5\u20136):143\u2013149","journal-title":"Genet Anal"},{"issue":"2","key":"404_CR31","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0378-1119(98)00567-8","volume":"226","author":"E Lundqvist","year":"1999","unstructured":"Lundqvist E, Johansson I, Ingelman-Sundberg M (1999) Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226(2):327\u2013338","journal-title":"Gene"},{"issue":"6","key":"404_CR32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2165\/00003088-198005060-00004","volume":"5","author":"CG Regardh","year":"1980","unstructured":"Regardh CG, Johnsson G (1980) Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet 5(6):557\u2013569","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"404_CR33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s002280050495","volume":"54","author":"R Koytchev","year":"1998","unstructured":"Koytchev R, Alken RG, Vlahov V, Kirkov V, Kaneva R et al (1998) Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol. Eur J Clin Pharmacol 54(6):469\u2013474","journal-title":"Eur J Clin Pharmacol"},{"issue":"19","key":"404_CR34","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","volume":"113","author":"SC Smith Jr","year":"2006","unstructured":"Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK et al (2006) AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113(19):2363\u20132372","journal-title":"Circulation"},{"issue":"3","key":"404_CR35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/clpt.1988.34","volume":"43","author":"S Toon","year":"1988","unstructured":"Toon S, Davidson EM, Garstang FM, Batra H, Bowes RJ, Rowland M (1988) The racemic metoprolol H2-antagonist interaction. Clin Pharmacol Ther 43(3):283\u2013289","journal-title":"Clin Pharmacol Ther"},{"key":"404_CR36","doi-asserted-by":"crossref","unstructured":"The MIAMI Trial Research Group (1985) Metoprolo in acute mycardial infarction. Other clinical findings and tolerability. Am J Cardiol 56(14):39G\u201346G","DOI":"10.1016\/0002-9149(85)90696-4"},{"key":"404_CR37","doi-asserted-by":"crossref","unstructured":"Herlitz J et al (2000) Long-term mortality after acute myocardial infarction in relation to prescribed dosages of a beta-blocker at hospital discharge. Cardiovasc Drugs Ther 14(6):589-595.","DOI":"10.1023\/A:1007894210131"},{"issue":"4","key":"404_CR38","first-page":"513","volume":"23","author":"DS Mautz","year":"1995","unstructured":"Mautz DS, Nelson WL, Shen DD (1995) Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6. Drug Metab Dispos 23(4):513\u2013517","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"404_CR39","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2125.1999.00865.x","volume":"47","author":"N Brynne","year":"1999","unstructured":"Brynne N, Bottiger Y, Hallen B, Bertilsson L (1999) Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole. Br J Clin Pharmacol 47(2):145\u2013150","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"404_CR40","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/00004714-199806000-00004","volume":"18","author":"V \u00d6zdemir","year":"1998","unstructured":"\u00d6zdemir V, Naranjo CA, Shulman RW, Herrmann N et al (1998) Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol 18(3):198\u2013207","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"404_CR41","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clpt.2006.08.004","volume":"80","author":"PA Thurmann","year":"2006","unstructured":"Thurmann PA, Haack S, Werner U, Szymanski J et al (2006) Tolerability of beta-blockers metabolized via cytochrome P450 2D6 is sex-dependent. Clin Pharmacol Ther 80(5):551\u2013553","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-007-0404-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-007-0404-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-007-0404-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T08:51:45Z","timestamp":1558687905000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-007-0404-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,29]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["404"],"URL":"https:\/\/doi.org\/10.1007\/s00228-007-0404-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,29]]}}}